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Research Article
Introduction
A systematic review of surveys on complementary and alter-
native medicine (CAM) use among cancer patients in North 
America, Europe, and Australia/New Zealand found that the 
United States has the highest CAM use among cancer 
patients, and its CAM use has been increasing over the past 
3 decades.1 The CAM prevalence among cancer patients 
was estimated at around 60% to 80%, but it depends on fac-
tors such as cancer type, sampling methods, time recalls, and 
decade of study.1-6
Cancer care providers’ knowledge of their patients’ 
CAM use is becoming important because of potential inter-
actions with routine cancer treatments.7,8 Cancer survivors 
are more likely to use CAM because of recommendations 
from their providers and are more likely to disclose their 
CAM use to their provider than noncancer controls,9 
although the nondisclosure rate still remains high, estimated 
at around 80% (77% to 84%).9,10
The majority of studies on CAM use among cancer patients 
do not specify the time periods in relation to cancer diagnoses, 
or the time periods of CAM use are highly varied among 
included individuals.1 Having information on CAM use over 
different time periods in relation to cancer diagnosis will 
allow investigation of change in patient behavior, thus facili-
tating patient-provider discussion of the risks of benefit and 
harm of CAM use over these time periods and referring 
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Abstract
Background. Complementary and alternative medicine (CAM) use is common among cancer patients, but the majority of 
CAM studies do not specify the time periods in relation to cancer diagnoses. We sought to define CAM use by cancer 
patients and investigate factors that might influence changes in CAM use in relation to cancer diagnoses. Methods. We 
conducted a cross-sectional survey of adults diagnosed with breast, prostate, lung, or colorectal cancer between 2010 and 
2012 at the Lineberger Comprehensive Cancer Center. Questionnaires were sent to 1794 patients. Phone calls were made to 
nonrespondents. Log binomial/Poisson regressions were used to investigate the association between cancer-related changes 
in CAM use and conversations about CAM use with oncology providers. Results. We received 603 (33.6 %) completed 
questionnaires. The mean age (SD) was 64 (11) years; 62% were female; 79% were white; and 98% were non-Hispanic. 
Respondents reported the following cancer types: breast (47%), prostate (27%), colorectal (14%), lung (11%). Eighty-nine 
percent reported lifetime CAM use. Eighty-five percent reported CAM use during or after initial cancer treatment, with 
category-specific use as follows: mind-body medicine 39%, dietary supplements 73%, body-based therapies 30%, and energy 
medicine 49%. During treatment CAM use decreased for all categories except energy medicine. After treatment CAM 
use returned to pretreatment levels for most CAMs except chiropractic. Initiation of CAM use after cancer diagnosis 
was positively associated with a patient having a conversation about CAM use with their oncology provider, mainly 
driven by patient-initiated conversations. Conclusions. Consistent with previous studies, CAM use was common among our 
study population. Conversations about CAM use with oncology providers appeared to influence cessation of mind-body 
medicine use after cancer diagnosis.
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patients to providers who are trained to discuss CAM. When 
this information is combined with information on patient-pro-
vider communication, it can provide insight into the role of 
patient-provider communication in cancer patients’ CAM use.
Using a questionnaire-based survey, we aimed to yield 
point estimates of CAM use among adult cancer patients 
treated in the past 2 years with the 4 most common cancers: 
breast, lung, prostate, or colorectal. Specifically, we assessed 
CAM in the following 3 time periods: before, during, and 
after initial cancer treatment in order to identify cancer-related 
changes in CAM use. We also investigated the communica-
tion patterns between patients and oncology providers and 
how that was associated with cancer-related CAM change.
Methods
Study Population
We conducted a cross-sectional survey of adult cancer 
patients seeking care at the North Carolina Cancer Hospital 
(NCCH) between 2010 and 2012. Eligible participants 
were English-speaking, between 21 and 99 years of age, 
and diagnosed with breast, prostate, lung, or colorectal 
cancer between 2010 and 2012. Participants were identi-
fied from the University of North Carolina (UNC) Tumor 
Registry, which is a comprehensive database of patients 
diagnosed with cancer at the NCCH, the clinical home of 
the Lineberger Comprehensive Cancer Center (LCCC). 
Potential participants were mailed an introductory letter, 
questionnaire, and a return-postage envelope. Follow-up 
telephone call and a second questionnaire were sent to non-
respondents. We made up to 3 attempts to contact patients 
by telephone. The Institutional Review Board at UNC 
approved the research protocol, and all study participants 
gave informed consent.
Data Collection
We adapted a questionnaire used by Richardson et al11 to 
assess CAM use at a comprehensive cancer center. We asked 
about CAM use in 4 primary categories: mind-body medi-
cine, dietary supplements, body-based therapies, and energy 
medicine. We also queried use of whole medical systems 
such as traditional Chinese medicine and ayurveda. 
Respondents were asked to indicate whether they had ever 
used specific CAM therapies in each of these categories, and 
if so, when that use occurred in relation to their initial cancer 
treatment (ie, before, during, or after). Information on sources 
of advice on CAM use and discussion of CAM use with 
oncology providers was also gathered. The questionnaire was 
pilot-tested on volunteers for readability and face validity. 
The tumor registry provided demographic and clinical data 
such as diagnosis date, tumor type and stage, and treatment 
history.
Statistical Analysis
We provide descriptive data for age, sex, as well as cancer 
type and stage, in addition to prevalence of CAM use (fre-
quency, percentage). Patients with stage 0 and stage 1 can-
cers were combined into an “early-stage cancer” group 
because of their prognostic and treatment similarities when 
compared with later-stage cancers.
We used log-binomial and Poisson regression to investi-
gate how communication of CAM was associated with 
changes in CAM use after cancer diagnosis. For all regres-
sions, we started with the full model that included variables 
such as age, education level, cancer type and cancer stage, 
and ran backward elimination to come up with the most 
succinct model (likelihood ratio test cutoff P = .05). All 
breast cancer cases were female, all prostate cancer cases 
were male, so following previous studies, we did not adjust 
for sex in these regressions.4 The analyses were performed 
using Stata IC Version 12 (StataCorp, College Station, TX).
Results
We sent out 1794 questionnaires and received 603 (33.6%) 
completed questionnaires. The mean age of respondents 
was 63.5 (±11.0) years. Sixty-two percent of respondents 
were female, 79% were white, and 98% were non-Hispanic. 
Compared with nonrespondents, respondents were more 
likely to be white (79.3% vs 68.4%), female (61.7% vs 
55.3%), have breast cancer (46.9% vs 39.4%), and have 
early-stage cancer (46.4% vs 39.5%; Table 1).
Eighty-nine percent of respondents reported ever using a 
CAM therapy during their lifetime. CAM use appeared to 
decrease during active cancer treatment compared with use 
prior to treatment for all CAM categories except energy 
medicine, which was largely driven by prayer and spiritual 
healing practices (Figure 1). CAM use was common both 
during and after cancer treatment for all CAM therapy cat-
egories. The most common therapies used included: vita-
min and mineral supplements (56% and 66%, during and 
after treatment, respectively); prayer and spiritual healing 
(46% and 43%); herbal supplements (25% and 32%), mas-
sage and movement therapy (16% and 24%); and deep 
breathing exercises (16% and 19%). Use of CAM therapies 
after treatment returned to pretreatment levels for most 
CAMs with the exception of chiropractic, which dropped 
during active treatment and remained low after treatment 
(20% vs 5% vs 9%).
In the periods after cancer diagnosis (ie, during and after 
cancer treatment), 85% of respondents reported using at 
least one CAM therapy. CAM use was most common 
among breast cancer patients (93%), followed by colorectal 
cancer (83%), prostate cancer (77%), and lung cancer (77%; 
Table 2). For patients of each of the 4 cancer types, dietary 
supplements were the most commonly used CAM modality 
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(52% to 82%), followed by energy medicine (39% to 55%), 
mind-body medicine (16% to 52%), and body-based ther-
apy (14% to 42%).
Most patients who used CAM therapy during or after 
cancer treatment were likely to use more than 1 CAM ther-
apy simultaneously (58%; Table 3). Twenty-eight percent of 
respondents reported using only 1 CAM therapy, which was 
most often a dietary supplement (71%).
Twenty-three percent (136/603) of all respondents 
reported having a conversation about CAM with their 
oncology provider. Initiation of CAM use any time after 
cancer diagnosis was positively associated with a patient 
having a conversation about CAM use with their oncology 
provider (Table 4). Further analysis revealed the increased 
likelihood of new CAM use was more driven by patient-
provider interactions in which patients initiated conversa-
tion about CAM, rather than CAM conversations initiated 
by cancer care provider (data not shown). Cessation of 
CAM therapy use during or after initial cancer treatment, on 
the other hand, was negatively associated with patient-pro-
vider conversation for MBM (prevalence ratio = 0.46, 95% 
CI = 0.22-0.93; Table 5). In other words, patients who had 
conversations with providers were less likely to cease MBM 
therapies during or after initial cancer treatment. We found 
no association between cancer type and either initiation or 
cessation of CAM use. We found no association between 
more advanced cancer stage and number of CAM therapies. 
We found no association between the type of treatment and 
CAM use or change (initiation and cessation) in CAM use 
since diagnosis.
Discussion
We set out to describe CAM use among cancer patients, as 
well as the communication pattern between patients and 
provider and its association with patients’ CAM use. We 
collected data on CAM use before, during, and after initial 
cancer treatment using a cancer patient sample at University 
of North Carolina Cancer Hospital, which allowed us to 
investigate changes in CAM use over time. We had data for 
discrete time periods related to time of diagnosis, which 
helped us understand CAM use before, during, and after 
treatment.
We found high lifetime CAM use (89%) in our popula-
tion. The response rate is slightly higher among breast can-
cer patients, a subgroup that is known to use CAM therapies 
more than patients of other cancer types. Nevertheless, this 
prevalence is similar compared to previous studies in can-
cer populations.11 Richardson et al11 found 83% of the can-
cer patients used at least 1 CAM therapy. Yates et al12 found 
CAM use as high as 91% among cancer patients during che-
motherapy and radiation. However, differences in the defi-
nition of CAM modalities for each study may confound 
comparison of these prevalence estimates. For example, 
Yates et al12 found that “prayer,” “relaxation,” and “exer-
cise” were the most commonly used CAM therapies. But, 
our question about prayer defined the activity as “prayer for 
healing” rather than a general question about any prayer. 
Not surprisingly, our estimates for prayer were lower than 
those reported by Yates et al12 (45% vs 77%, respectively). 
Similarly, we asked about specific exercises such as T’ai 
chi, Qiqong, and yoga, rather than a general question about 
exercise. Accordingly, we found that during initial cancer 
treatment, dietary supplements, not prayer or exercise, were 
the most common CAM therapy used, followed by energy 
medicine (in which prayer is the main driver), and then 
mind-body medicine, and body-based therapies. Dietary 
supplements have been reported to be the most common 
CAM therapy in a few other studies, including one study 
that used the 2007 National Health Interview Survey.4,13
We found that CAM use generally decreased during 
active cancer treatment compared with use prior to diagno-
sis and returned to pretreatment levels after completion of 
cancer treatment. Notable exceptions to this trend were sus-
tained levels of prayer, spiritual healing, deep breathing 
exercise, and light/magnet therapy during cancer treatment. 
The reason for the decrease of CAM use during cancer 
treatment may be 2-fold. First, doctors and health providers 
might have spoken to patients and advised against CAM 
use, although in our study we did not collect data on whether 
the doctor recommended for or against CAM use. Second, 
when patients are diagnosed with cancer and start the sub-
sequent counseling and treatment, the process is complex 
and cognitively taxing for the patients. Such large cognitive 
load and high volume of complex decision making have 
Table 1. Characteristic of Respondents and Nonrespondents.
Characteristics
Respondents 
(N = 603)
Nonrespondents 
(N = 1189)
Age, years, mean (SD) 63.5 (11.0) 61.1 (12.0)
Sex, female, n (%) 372 (61.7) 657 (55.3)
Race, white, n (%) 476 (78.9) 809 (68.0)
Ethnicity, non-Hispanic, n (%) 591 (98.0) 1141 (96.0)
Cancer type, n (%)  
 Breast 283 (46.9) 468 (39.4)
 Prostate 164 (27.2) 331 (27.8)
 Colorectal 87 (14.4) 221 (18.6)
 Lung 69 (11.4) 169 (14.2)
Cancer stage,a n (%)  
 0-1 278 (46.4) 463 (39.5)
 2 214 (35.7) 450 (38.4)
 3 68 (11.4) 158 (13.5)
 4 39 (6.5) 102 (8.7)
aOf all surveyed participants (respondents and nonrespondents), 160 
were cancer stage “0” and 581 patients were stage “1.” Among 160 
stage “0” participants, 144 (90%) had breast cancer; among 581 stage “1” 
patients, 259 (45%) had breast cancer. Nine patients’ cancer stage was 
unknown.
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been linked to decision fatigue and thus decision simplifica-
tion strategies.14-16
Interestingly, posttreatment levels of chiropractic 
remained low, suggesting patients may have been uncom-
fortable returning to that therapy based on their cancer 
diagnosis.
For patients’ CAM use by cancer types, we found the 
highest CAM use among breast cancer patients, followed 
by colorectal cancer patients, and then prostate and lung 
cancer patients. A similar pattern across cancer types is also 
seen in a few other studies. For example, Patterson et al,4 
using a telephone survey of cancer patients identified from 
the population-based Cancer Surveillance System of 
Western Washington, found that CAM use was highest 
among breast cancer patients (87%), followed by colorectal 
(64%) and prostate (59%) cancer patients. Lafferty et al,17 
using a registry-matched insurance claims database, also 
noted a similar pattern: Compared with colorectal cancer 
patients, breast cancer patients had higher CAM use during 
initial treatment and continued use after treatment (odds 
ratio [OR] = 1.85, 95% CI =1.19-2.87 and OR = 2.04, 95% 
CI = 1.29-3.22, respectively), prostate cancer patients has 
slightly higher or similar CAM use (OR = 1.13, 95% CI = 
0.71-1.81 and OR = 1.28, 95% CI = 0.79-2.09, respectively) 
Table 2. CAM Use During or After Initial Cancer Treatment for Each Cancer Type.
Cancer Type
CAM Use by CAM Therapy Category, n (%)
Any CAM MBM DS BBT EM
All (N = 603) 514 (85.2) 236 (39.1) 437 (72.5) 181 (30.0) 294 (48.8)
Breast (n = 283) 262 (92.6) 148 (52.3) 231 (81.6) 120 (42.4) 156 (55.1)
Prostate (n = 164) 127 (77.4) 26 (15.9) 103 (62.8) 23 (14.0) 66 (40.2)
Colorectal (n = 87) 72 (82.8) 38 (43.7) 63 (72.4) 22 (25.3) 45 (51.7)
Lung (n = 69) 53 (76.8) 24 (34.8) 40 (58.0) 16 (23.2) 27 (39.1)
Abbreviations: CAM, complementary and alternative medicine; MBM, mind-body medicine; DS, dietary supplement; BBT, body-based therapy; EM, 
energy medicine.
Figure 1. Complementary and alternative medicine (CAM) therapy use before, during, and after active cancer treatment (N = 603). 
Each graph depicts total proportion of participants that used at least one therapy for that category of CAM therapy (diamond lines). 
Proportions for individual CAM therapies are represented in the lower lines. For example, during cancer treatment, about 59% of our 
population reported taking a dietary supplement (Figure 1b). Almost all participants who reported taking a supplement took a vitamin 
or mineral supplement (square line), and about 44% (0.26/0.59) reported taking an herbal or other type of supplement (triangle line).
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during and after treatment, followed by lung cancer patients 
(OR = 1.31, 95% CI = 0.72-2.38 and OR = 1.05, 95% CI = 
0.53-2.07, respectively).
We found that initiation of CAM therapy across all four 
CAM categories during and after cancer treatment was pos-
itively associated with having a conversation about CAM 
with an oncology provider. Although we do not have infor-
mation on the content of those conversations, our data show 
that patients who initiated a conversation with their medical 
provider about CAM use were also more likely to initiate 
new CAM use after diagnosis. Although it is possible that 
some oncology providers may have been suggesting use of 
some CAM therapies, it is more likely that patients who 
were motivated to discuss CAM therapies with their provid-
ers were also strongly motivated to use them prior to their 
discussions.
Our findings have implications for communications 
between oncology providers and cancer patients. First, 
patients who initiate a conversation about CAM are more 
likely to initiate CAM use. In their communications about 
CAM therapies with providers, patients often recognize that 
medical providers are typically not CAM experts and they 
are especially concerned about negative responses from 
their providers.18 While most cancer patients use CAM in 
order to boost the immune system, relieve pain, and control 
side effects as a result of disease or treatment,19 they are 
typically looking for the best of both worlds: CAM plus 
conventional cancer treatment together.20 However, nondis-
closure of CAM use to cancer care providers remains com-
mon.18,21 Given the high prevalence of CAM use among 
cancer patients, emerging evidence that certain CAM thera-
pies can improve patient quality of life and reduce treatment 
and disease-related symptoms, and the potential interaction 
between some CAM therapies and conventional cancer 
treatment, we encourage oncology providers to discuss 
CAM use with their patients in an open and nonjudgmental 
fashion in order to facilitate patient-centered communica-
tion as well as participatory patient decision making.22
Second, if oncology providers wish to influence their 
patient’s decisions about CAM use, they may need to use 
additional strategies and resources to help them. For exam-
ple, recommendations about specific dietary supplement-
drug interactions may be more persuasive for patients 
compared to general recommendations to avoid supple-
ments altogether during treatment. Where oncologists do 
not have such expertise, cancer centers could employ phar-
macy and CAM specialists who are trained to discuss sup-
plement-drug interactions.
Limitations
Our response rate was low, which may bias our prevalence 
estimates for overall CAM use. However, the rate of CAM 
use among respondents was very high, suggesting that our 
sample may have included most of the CAM users among 
our patient population. As such, the information we have on 
communication among CAM users remains relevant, espe-
cially for the early stage cancers were the response rates 
were highest. Additionally, we can estimate CAM use preva-
lence using sensitivity analysis. For example, assuming that 
Table 3. Number of Complementary and Alternative Medicine 
Therapies Used During or After Cancer Treatment.
Cancer Type
Number of Therapies Used, n (%)
0 1 >1
Breast (n = 283) 21 (7.4) 61 (21.6) 201 (71.0)
Prostate (n = 164) 37 (22.6) 65 (39.6) 62 (37.8)
Colorectal (n = 87) 15 (17.2) 22 (25.3) 50 (57.5)
Lung (n = 69) 16 (23.2) 19 (27.5) 34 (49.3)
All respondents (N = 603) 89 (14.8) 167 (27.7) 347 (57.6)
Table 4. Association of New CAM Use After Cancer Diagnosis 
and Conversation About CAM With Oncology Provider.
CAM 
Therapy
No CAM 
Use Prior to 
Diagnosis, n
New CAM Use 
After Diagnosis,a 
n (%)
Prevalence 
Ratio (95% CI)b P
MBM 366 52 (14.2) 1.79 (1.07-2.99) .03
DS 162 63 (38.9) 1.83 (1.05-3.19) .03
BBT 401 46 (11.5) 3.31 (1.85-5.94) .00
EM 321 38 (11.8) 2.83 (1.48-5.44) .00
Abbreviations: CAM, complementary and alternative medicine; MBM, 
mind-body medicine; DS, dietary supplement; BBT, body-based therapy; 
EM, energy medicine.
aNew CAM use is defined as CAM therapy use changed from “No” 
before cancer diagnosis to “Yes” after cancer diagnosis.
bModel adjusted for age, education, cancer type and cancer stage for 
MBM; adjusted for cancer type, cancer stage for DS; adjusted for cancer 
type for BBT, adjusted for age for EM.
Table 5. Association of Cessation of CAM Use After Cancer 
Diagnosis With Conversation About CAM With Oncology 
Provider.
CAM 
Therapy
CAM Use 
Prior to 
Diagnosis, n
Cessation of 
CAM Use After 
Diagnosis,a n (%)
Prevalence 
Ratio with 95% 
CIb P
MBM 210 57 (27.1) 0.46 (0.22-0.93) .03
DS 414 111 (26.8) 0.85 (0.57-1.28) .44
BBT 175 97 (55.4) 0.87 (0.63-1.19) .37
EM 255 19 (7.5) 1.57 (0.65-3.84) .32
Abbreviations: CAM, complementary and alternative medicine; MBM, 
mind-body medicine; DS, dietary supplement; BBT, body-based therapy; 
EM, energy medicine.
aCessation of CAM usage is defined as CAM therapy use changed from 
“Yes” before active cancer treatment to “No” during/after cancer 
treatment.
bModel adjusted for cancer type.
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only 10% of nonrespondents used CAM therapies during or 
after cancer diagnosis on the lower boundary and 30% were 
CAM users on the upper boundary (514/1794 = 29%), then 
we can estimate the prevalence of CAM use during or after 
cancer treatment lies between 37% and 49%. Second, this is 
a retrospective study, and we relied on participants for the 
accuracy and completeness of their responses. Third, we did 
not collect information on other possible factors which may 
affect patients’ CAM uptake and change in CAM use. Last, 
we recognize that advanced-stage cancer patients were only 
6.5% of our study population and as a result our study results 
may not fully represent patients with advanced cancers.
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